<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03863171</url>
  </required_header>
  <id_info>
    <org_study_id>2018-P2-185-02</org_study_id>
    <nct_id>NCT03863171</nct_id>
  </id_info>
  <brief_title>Early Diagnosis for Ocular Ischemia Syndrome Using Arterial Spin Labeling Magnetic Resonance Imaging Technique</brief_title>
  <official_title>Early Diagnosis for Ocular Ischemia Syndrome Using Arterial Spin Labeling Magnetic Resonance Imaging Technique: a Prospective Multicenter Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To evaluate ocular blood perfusion status and the possibility of craniocerebral vascular
           lesions of patients with ocular ischemia syndrome (OIS) using arterial spin labeling
           (ASL) magnetic resonance imaging technique.

        2. To evaluate the specificity, sensitivity and accuracy of arterial spin labeling (ASL)
           magnetic resonance imaging technique in OIS diagnosis, compared with the traditional
           routine examination method.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Flow (BF)</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Blood Flow (BF)ï¼ša parameter measured by arterial spin labeling perfusion MRI to qualify the perfusion in tissue-specific units (ml blood/gram tissue/time)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Ocular Ischemia Syndrome</condition>
  <arm_group>
    <arm_group_label>Ocular ischemia syndrome</arm_group_label>
    <description>Patients with ocular ischemia syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients with age-related macular degeneration</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Arterial spin labeling (ASL) magnetic resonance imaging</intervention_name>
    <description>Arterial spin labeling (ASL) magnetic resonance imaging test</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Ocular ischemia syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fundus fluorescein angiography</intervention_name>
    <description>Fundus fluorescein angiography test</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Ocular ischemia syndrome</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ocular ischemia syndrome
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ocular ischemia syndrome group: Patients diagnosed with ocular ischemia syndrome;

          -  Age-related macular degeneration group (Control group): Patients diagnosed with
             age-related macular degeneration;

          -  Age: 50-80 years;

          -  Sex: all;

          -  Patients signed written informed consent.

        Exclusion Criteria:

          -  Fundus fluorescein angiography (FFA) clear images cannot be obtained due to refractive
             media problems(such as corneal leukoplakia, severe cataract, vitreous hemorrhage,
             etc.) ;

          -  Patients with contraindications for FFA;

          -  Patients was unable to perform magnetic resonance rmaging (MRI) test;

          -  Patients with history of bleeding and cerebral infarction;

          -  Patients with a history of surgery within 3 months;

          -  Patients who had participated in other clinical trials within 3 months;

          -  Patients who disagree and refuse to participate in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Yanling Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanling Wang, MD</last_name>
    <phone>+86-13701277114</phone>
    <email>wangyanling999@vip.sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanling Wang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Yue Li</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

